Promoting Competition
and Investment in the
U.S. Life Sciences Ecosystem
The U.S. life sciences ecosystem depends on mergers and acquisitions (M&A) to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients.
PARTNERS
ABOUT US
PULSE is dedicated to raising awareness about the vital role of mergers and acquisitions (M&A) as well as other collaborations to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients. Our members represent frontline researchers, employees and leaders of life sciences companies of all sizes that support a diverse, vibrant life sciences ecosystem at the national level and in local communities. PULSE will help advance a national dialogue focused on fostering innovation across the life sciences while supporting a competitive U.S. market that delivers next generation treatments and cures
for patients.
LATEST NEWS
New PULSE Resources: M&A Fuels Innovation, Competition in America’s Life Sciences Industry
New resources from the Partnership for the U.S. Life Science Ecosystem (PULSE) highlight the unique and fundamental role of mergers and acquisitions (M&A) in America’s life sciences industry. Life sciences M&A represents a critical pathway for companies of all...
Maryland Daily Record Op-Ed: “Misguided Antitrust Policies Jeopardize Maryland Life Sciences Industry”
In a recent op-ed for The Maryland Daily Record, Kelly Schulz, CEO of PULSE Partner Maryland Tech Council, discusses discusses how federal policy against mergers and acquisitions (M&A) could undermine Maryland’s status as an innovation leader in the life sciences.
Innovations Advanced by M&A: A Novel Treatment for Atopic Dermatitis
For many early-stage life sciences companies, mergers and acquisitions (M&A) represent a critical path. M&A helps companies unlock the complementary resources and expertise that help advance a new therapy from the lab to patients at scale. For example, Dermira’s acquisition by Eli Lilly & Co. helped bring Ebglyss, a novel monoclonal antibody treatment, to patients living with moderate-to-severe atopic dermatitis (AD).